Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma

BACKGROUND: In a randomized phase III trial of sunitinib vs interferon-alfa (IFN-α) in metastatic renal cell carcinoma (mRCC), better baseline quality of life (QoL) was predictive of longer survival. Using this dataset, we have developed a novel prognostic tool that establishes a relationship betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: Cella, D, Bushmakin, A G, Cappelleri, J C, Charbonneau, C, Michaelson, M D, Motzer, R J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322947/
https://www.ncbi.nlm.nih.gov/pubmed/22240794
http://dx.doi.org/10.1038/bjc.2011.589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322947/
https://www.ncbi.nlm.nih.gov/pubmed/22240794
http://dx.doi.org/10.1038/bjc.2011.589

Ejemplares similares